Slingsby
Brian Peter Slingsby, Welwyn GB
Patent application number | Description | Published |
---|---|---|
20100041654 | Pyrimidine Derivatives And Their Use As CB2 Modulators - This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor. | 02-18-2010 |
Jason Slingsby, Wien AT
Patent application number | Description | Published |
---|---|---|
20120288474 | COMPOSITION FOR TREATMENT OF CXCL8-MEDIATED LUNG INFLAMMATION - The present invention provides a composition comprising a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated GPCR activity compared to the respective wild type IL-8 for use in preventing or treating lung inflammation with neutrophilic infiltration, for example for the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, broncheolitis, acute lung injury and acute respiratory distress syndrome. | 11-15-2012 |
Jason Slingsby, Vienna AT
Patent application number | Description | Published |
---|---|---|
20100298203 | SDF-I-BASED GLYCOSAMINOGLYCAN ANTAGONISTS AND METHODS OF USING SAME - The present invention relates to novel mutants of human stromal cell-derived factor-1 which exhibit increased glycosaminoglycan (GAG) binding affinity and inhibited or down-regulated GPCR activity compared to wild type SDF-1, methods for producing these mutants and to their use for preparing medicaments for the treatment of cancer. | 11-25-2010 |
Paul Slingsby, Queensland AU
Patent application number | Description | Published |
---|---|---|
20100282043 | PLECTRUM - The invention relates to a plectrum for playing a stringed instrument. The plectrum is adapted to be securable relative to a finger (or thumb) of an instrument player, and it has a string engaging portion and a finger engaging portion. The finger engaging portion (or at least a part of it) has a spiral configuration which can secure the plectrum relative to the finger (or thumb) when the plectrum is positioned with the spiral at least partly wound around an end or portion of the finger (or thumb). | 11-11-2010 |
Robert Slingsby, Santa Fe, NM US
Patent application number | Description | Published |
---|---|---|
20090095281 | Heliostat with Actively Controlled Liquid Ballast System - A heliostat having a frame structure for supporting a mirror. The frame structure is pivotable about at least one axis of rotation. A liquid ballast system is mounted on a side of the frame structure that is remote from the reflective surface of the mirror. The liquid ballast system includes at least two tanks, and an imaginary line between the tanks extends at an angle or perpendicular to the axis of rotation. An arrangement is provided for moving ballast liquid between the tanks in an actively controlled manner. | 04-16-2009 |
Rosanne W. Slingsby, Pleasanton, CA US
Patent application number | Description | Published |
---|---|---|
20150182875 | ION EXCHANGE FOAMS TO REMOVE IONS FROM SAMPLES - A method of making an ion exchange foam is described. The method includes forming an aqueous phase by suspending an ion exchange resin in an aqueous solvent. An organic phase is formed by mixing at least a divinylbenzene, a monomer, and a surfactant. The formed aqueous phase is mixed with the formed organic phase to form an emulsion. The emulsion is polymerized to form the ion exchange foam. The ion exchange foam can be used with a plurality of sample vials in an autosampler. | 07-02-2015 |
Rosanne Williamson Slingsby, Pleasanton, CA US
Patent application number | Description | Published |
---|---|---|
20130309777 | SURROGATE ADDITION DEVICE AND A METHOD OF ANALYTE CONCENTRATION - A surrogate addition device is described that adds a surrogate compound at a uniform transport rate to a flowing sample stream. The surrogate addition device includes a surrogate reservoir, a flow chamber, and a diffusion barrier. The surrogate reservoir can be configured to contain a surrogate solution where the surrogate solution includes a surrogate compound. The flow chamber includes an inlet port and an outlet port. At least a portion of the diffusion barrier is disposed in between the surrogate reservoir and the flow chamber. The diffusion barrier may include an inner surface that forms a wall of the surrogate reservoir, and an outer surface that forms a wall of the flow chamber. The flow chamber can be configured to receive a flowing sample solution across the outer surface of the diffusion barrier and also to diffuse the surrogate compound from the surrogate reservoir to the flow chamber. | 11-21-2013 |